- Email: [email protected]
TSLC1 in leukemic cutaneous T-cell lymphoma: A possible diagnostic marker for Sézary syndrome
Abstracts / Journal of Dermatological Science 84 (2016) e1–e88
P04-07[C03-05]
P04-08[C03-06]
The expression of CADM1/TSLC1 in leukemic cutaneous T-cell lymphoma: A possible diagnostic marker for Sézary syndrome
The serum levels of squamous cell carcinoma antigens 1 and 2 are associated with severity and clinical types of atopic dermatitis
Mari Yamaguchi 1,∗ , Toshihisa Hamada 1 , Masahide Imada 2 , Toshiyuki Watanabe 2 , Ken Okada 2 , Keiji Iwatsuki 1
Tomoko Okawa 1,∗ , Yukie Yamaguchi 1 , Kevin Kou 1 , Junya Ono 2 , Yusuke Inoue 1 , Masumi Kohno 3 , Setsuko Matsukura 3 , Takeshi Kambara 3 , Shoichiro Ohta 4 , Kenji Izuhara 5 , Michiko Aihara 1
1 Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Division of Medical Support of Okayama University Hospital, Okayama, Japan
Cell Adhesion Molecule 1 (CADM1/TSLC1) is known to be expressed in adult T-cell leukemia/lymphoma (ATLL) cells as well as other cancer cells. To explore a potential biomarker for primary cutaneous T-cell lymphoma (CTCL), we examined the CADM1/TSLC1 expression in leukemic cells from three patients with Sézary syndrome (SS), and three cell lines established from patients with mycosis fungoides (MF)/SS. As a control, we examined the expression in four and two cell lines derived from anaplastic large cell lymphoma (ALCL) and ATLL, respectively, normal peripheral blood mononuclear cells (PBMCs), and reactive lymphocytosis in patients with mycosis fungoides (MF) (n = 9) and non-CTCL erythroderma (n = 4), including actinic reticuloid, non-clonal CD8+ T-cell atypical lymphocytosis, drug- induced erythroderma, and erythroderma of unknown etiology. In all three patients with SS, the CADM1/TSLC1+ cells were increased to 65.1%, 38.0% and 74.5% in the CD3+CD4+ cell fractions, respectively, but absent or a background level in normal PBMCs and reactive lymphocytosis. In conventional Sézary cell markers, the CD4+CD7- and CD4+CD26cells were observed in 82.7% and 97.7%, 9.6% and 92.4%, and 84.0% and 83.6%, respectively, in the three patients. In the cell lines examined, the CADM1/TSLC1+ cells ranged from 8.0 to 99.7% and 11.3 to 22.4% in the MF/SS- and ATLL-derived cell lines, respectively, whereas they ranged from 1.3 to 7.5% in the ALCL cell lines. These results indicate that the CADM1/TSLC1 is expressed frequently in the leukemic cells of MF/SS and ATLL, and suggest that the CADM1/TSLC1 is an additional diagnostic marker for the B2 criteria of leukemic CTCL, or Sézary syndrome, and might be a therapeutic target. http://dx.doi.org/10.1016/j.jdermsci.2016.08.102
e31
1
Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan 2 Shino-Test Corporation, Sagamihara, Japan 3 Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan 4 Department of Laboratory Medicine, Saga Medical School, Saga, Japan 5 Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan Background: Squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 are members of the family of serine protease inhibitors induced by Th-2 type cytokines such as IL-4 and IL-13. Recent studies suggest that SCCA1 and SCCA2 play an important role in allergic diseases correlate with disease severity in atopic dermatitis (AD) and bronchial asthma. Objective: To investigate whether serum SCCA1 and SCCA2 levels are associated with the clinical phenotype in adult patients with AD. Methods: An enzyme-linked immunosorbent assay was performed to examine serum SCCA1 and SCCA2 levels in 257 adult patients with AD and in 25 healthy controls. Serum SCCA1 and SCCA2 levels were analyzed with clinical characteristics and laboratory parameters including thymus and activationregulated chemokine (TARC), lactate dehydrogenase (LDH), blood eosinophils, and total IgE. The effects of treatment on serum SCCA1 and SCCA2 levels were also assessed. Results: The serum SCCA1 and SCCA2 levels were significantly higher in AD patients than that in healthy controls. Positive correlations were observed in disease severity, levels of TARC, LDH, eosinophil account, but not in IgE level. The serum levels of SCCA1 and SCCA2 were higher in erythroderma type and widespread type of AD compared with that in other types. Serial measurement of serum SCCA1 and SCCA2 revealed decreased levels of SCCA1 and SCCA2 after treatment for AD. Conclusion: Our results suggest that the levels of serum SCCA1 and SCCA2 reflected disease severity and clinical types of AD. Serum SCCA1 and SCCA2 are novel biomarkers of evaluating accurate disease activity and treatment efficacy. http://dx.doi.org/10.1016/j.jdermsci.2016.08.103
P04-07[C03-05]
P04-08[C03-06]
The expression of CADM1/TSLC1 in leukemic cutaneous T-cell lymphoma: A possible diagnostic marker for Sézary syndrome
The serum levels of squamous cell carcinoma antigens 1 and 2 are associated with severity and clinical types of atopic dermatitis
Mari Yamaguchi 1,∗ , Toshihisa Hamada 1 , Masahide Imada 2 , Toshiyuki Watanabe 2 , Ken Okada 2 , Keiji Iwatsuki 1
Tomoko Okawa 1,∗ , Yukie Yamaguchi 1 , Kevin Kou 1 , Junya Ono 2 , Yusuke Inoue 1 , Masumi Kohno 3 , Setsuko Matsukura 3 , Takeshi Kambara 3 , Shoichiro Ohta 4 , Kenji Izuhara 5 , Michiko Aihara 1
1 Department of Dermatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan 2 Division of Medical Support of Okayama University Hospital, Okayama, Japan
Cell Adhesion Molecule 1 (CADM1/TSLC1) is known to be expressed in adult T-cell leukemia/lymphoma (ATLL) cells as well as other cancer cells. To explore a potential biomarker for primary cutaneous T-cell lymphoma (CTCL), we examined the CADM1/TSLC1 expression in leukemic cells from three patients with Sézary syndrome (SS), and three cell lines established from patients with mycosis fungoides (MF)/SS. As a control, we examined the expression in four and two cell lines derived from anaplastic large cell lymphoma (ALCL) and ATLL, respectively, normal peripheral blood mononuclear cells (PBMCs), and reactive lymphocytosis in patients with mycosis fungoides (MF) (n = 9) and non-CTCL erythroderma (n = 4), including actinic reticuloid, non-clonal CD8+ T-cell atypical lymphocytosis, drug- induced erythroderma, and erythroderma of unknown etiology. In all three patients with SS, the CADM1/TSLC1+ cells were increased to 65.1%, 38.0% and 74.5% in the CD3+CD4+ cell fractions, respectively, but absent or a background level in normal PBMCs and reactive lymphocytosis. In conventional Sézary cell markers, the CD4+CD7- and CD4+CD26cells were observed in 82.7% and 97.7%, 9.6% and 92.4%, and 84.0% and 83.6%, respectively, in the three patients. In the cell lines examined, the CADM1/TSLC1+ cells ranged from 8.0 to 99.7% and 11.3 to 22.4% in the MF/SS- and ATLL-derived cell lines, respectively, whereas they ranged from 1.3 to 7.5% in the ALCL cell lines. These results indicate that the CADM1/TSLC1 is expressed frequently in the leukemic cells of MF/SS and ATLL, and suggest that the CADM1/TSLC1 is an additional diagnostic marker for the B2 criteria of leukemic CTCL, or Sézary syndrome, and might be a therapeutic target. http://dx.doi.org/10.1016/j.jdermsci.2016.08.102
e31
1
Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan 2 Shino-Test Corporation, Sagamihara, Japan 3 Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan 4 Department of Laboratory Medicine, Saga Medical School, Saga, Japan 5 Division of Medical Biochemistry, Department of Biomolecular Sciences, Saga Medical School, Saga, Japan Background: Squamous cell carcinoma antigens 1 (SCCA1) and SCCA2 are members of the family of serine protease inhibitors induced by Th-2 type cytokines such as IL-4 and IL-13. Recent studies suggest that SCCA1 and SCCA2 play an important role in allergic diseases correlate with disease severity in atopic dermatitis (AD) and bronchial asthma. Objective: To investigate whether serum SCCA1 and SCCA2 levels are associated with the clinical phenotype in adult patients with AD. Methods: An enzyme-linked immunosorbent assay was performed to examine serum SCCA1 and SCCA2 levels in 257 adult patients with AD and in 25 healthy controls. Serum SCCA1 and SCCA2 levels were analyzed with clinical characteristics and laboratory parameters including thymus and activationregulated chemokine (TARC), lactate dehydrogenase (LDH), blood eosinophils, and total IgE. The effects of treatment on serum SCCA1 and SCCA2 levels were also assessed. Results: The serum SCCA1 and SCCA2 levels were significantly higher in AD patients than that in healthy controls. Positive correlations were observed in disease severity, levels of TARC, LDH, eosinophil account, but not in IgE level. The serum levels of SCCA1 and SCCA2 were higher in erythroderma type and widespread type of AD compared with that in other types. Serial measurement of serum SCCA1 and SCCA2 revealed decreased levels of SCCA1 and SCCA2 after treatment for AD. Conclusion: Our results suggest that the levels of serum SCCA1 and SCCA2 reflected disease severity and clinical types of AD. Serum SCCA1 and SCCA2 are novel biomarkers of evaluating accurate disease activity and treatment efficacy. http://dx.doi.org/10.1016/j.jdermsci.2016.08.103